Announcements Trials

Browse Landscape

Phase

Phase 2 9 Phase 1 4 Phase NA 3 Phase EARLY_PHASE1 2 Phase 1/2 2 Phase 4 1 Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 35 Small Cell Lung Carcinoma 34 Leukemia 34 Lung Neoplasms 25 Leukemia, Myeloid, Acute 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Lymphoma, Large B-Cell, Diffuse 19 Neuroblastoma 15 Lymphoma, Non-Hodgkin 15 Carcinoma, Non-Small-Cell Lung 14 Leukemia, Erythroblastic, Acute 13 Hodgkin Disease 13 Leukemia, Myelomonocytic, Acute 12 Leukemia, Monocytic, Acute 12 Leukemia, Megakaryoblastic, Acute 12 Sarcoma 11 Lymphoma, Follicular 10 Burkitt Lymphoma 10 Lymphoma, Large-Cell, Immunoblastic 9 Testicular Neoplasms 7 Teratoma 7 Myelodysplastic Syndromes 7 Congenital Abnormalities 7 Multiple Myeloma 6 Endodermal Sinus Tumor 6 Anemia, Refractory, with Excess of Blasts 6 Testicular Germ Cell Tumor 5 Ovarian Neoplasms 5 Neuroectodermal Tumors, Primitive, Peripheral 5 Central Nervous System Neoplasms 5

Interventions

Vincristine 7 Cyclophosphamide 7 10-propargyl-10-deazaaminopterin 7 Prednisone 6 Doxorubicin 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5 romidepsin 3 belinostat 3 Gemcitabine 3 liposomal doxorubicin 2 duvelisib 1 Vitamin B 12 1 MLN 8237 1 Folic Acid 1 Etoposide 1 E7777 fusion protein 1 Decitabine 1 CHOP protocol 1 Brentuximab Vedotin 1 Bendamustine Hydrochloride 1 BAEC protocol 1 Alemtuzumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, T-Cell, Peripheral × Etoposide × Clear all

NCT07258680 2025-12-02

BrEto-TCL

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Enrolling by invitation

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡